<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann S LaCasce, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrea K Ng, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George P Canellos, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon category of Hodgkin lymphoma (HL). The pathobiology, pathologic features, clinical presentation, treatment, and prognosis distinguish NLPHL from other categories of HL, which are collectively referred to as classic HL (cHL). </p><p>In recognition of these distinctions, NLPHL was renamed "nodular lymphocyte-predominant B cell lymphoma" in the International Consensus Classification (ICC) of mature lymphoid neoplasms [<a href="#rid1">1</a>]. The 5th edition of the World Health Organization (WHO5) classification of hematolymphoid neoplasms maintained the name NLPHL [<a href="#rid2">2</a>].</p><p>The epidemiology, pathogenesis, clinical manifestations, pathology, diagnosis, and differential diagnosis of NLPHL are reviewed here.</p><p>Treatment and prognosis of NLPHL are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4732.html" rel="external">"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma"</a>.) </p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>NLPHL accounts for approximately 5 percent of patients diagnosed with Hodgkin lymphoma (HL) [<a href="#rid3">3</a>]. The incidence of NLPHL in the United States and Europe has been stable at approximately 8 to 9 cases per 10,000,000 people per year, but the incidence in children may be rising [<a href="#rid4">4,5</a>]. </p><p>Approximately 75 percent of patients with NLPHL are male [<a href="#rid4">4</a>]. The age distribution has two peaks: one in children and one in adults, the latter with a median age of 30 to 40 years [<a href="#rid6">6,7</a>]. In the United States, NLPHL is more common among Black Americans than White Americans, which distinguishes it from classic HL (cHL) [<a href="#rid4">4</a>].</p><p>NLPHL occurs with higher than expected frequency among first-degree family members of patients with NLPHL, as demonstrated by an analysis of 692 patients with NLPHL and their 4280 first-degree relatives in the Finnish Cancer Registry [<a href="#rid7">7</a>]. NLPHL, cHL, and non-Hodgkin lymphoma (NHL) were diagnosed in 9, 15, and 35 first-degree relatives, respectively. Compared with age-, sex-, and race-matched individuals from a general population, relatives of patients with NLPHL had a higher rate of developing NLPHL (standardized incidence ratio [SIR] 19; 95% CI 8.8-36), cHL (SIR 5.3; 95% CI 3-8.8), and NHL (SIR 1.9; 95% CI 1.3-2.6); the incidence of cancer overall was not increased in family members (SIR 1.1; 95% CI 1.1-1.2).</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The malignant cells of NLPHL are referred to here as lymphocyte predominant (LP) cells. For historical reasons and because of previous uncertainty about their nature, LP cells were formerly called lymphocytic-histiocytic variants by pathologists. </p><p>LP cells are derived from transformed germinal center B (GCB) cells, but the bulk of the tumor mass in NLPHL consists of abundant reactive (nonmalignant) cells that surround the LP cells. Although LP cells and the malignant Hodgkin/Reed-Sternberg (HRS) cells of classic Hodgkin lymphoma (cHL) are both derived from GCB cells, LP cells are morphologically distinct, are not associated with production of proinflammatory cytokines, utilize different mechanisms to sustain growth and survival, and are surrounded by a different mixture of reactive cells than those that surround HRS cells in cHL. The pathogenesis of cHL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma", section on 'Pathogenesis of cHL'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>LP cells, the malignant cells of NLPHL</strong> – The origin of LP cells from transformed GCB cells is demonstrated by the presence of productive immunoglobulin (Ig) rearrangements and somatic hypermutation of <em>Ig</em> genes [<a href="#rid8">8-10</a>]. LP cells (<a class="graphic graphic_picture graphicRef82911" href="/z/d/graphic/82911.html" rel="external">picture 1</a>) are morphologically distinct from HRS cells of cHL (<a class="graphic graphic_picture graphicRef69090" href="/z/d/graphic/69090.html" rel="external">picture 2</a>). (See <a class="local">'LP cells'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular/genetic findings</strong> – The genetic changes associated with NLPHL and how they contribute to the pathogenesis of NLPHL are not well characterized. Somatic hypermutation, which is a characteristic feature of GCB cells, may be misdirected (ie, off-target) in LP cells and contribute to some of the mutations associated with NLPHL. Like other GCB-derived tumors, rearrangements of <em>BCL6</em> are present in a minority of cases [<a href="#rid11">11</a>]. In some cases, loss-of-function mutations in <em>SOCS1</em> (a negative regulator of JAK-STAT signaling) can lead to hyperactivation of STAT6 [<a href="#rid12">12</a>]. In two cases of large cell transformation of NLPHL, next-generation sequencing (NGS) of LP cells reported mutations of <em>SOCS1</em>, <em>JUNB</em> (transcription factor JunB), <em>DUSP2</em> (dual specificity protein phosphatase 2), and <em>SGK1</em> (serum/glucocorticoid regulated kinase 1), but the roles of these mutations in the pathogenesis of NLPHL remain to be defined [<a href="#rid13">13</a>]. Chronic antigenic stimulation by the common bacterium, <em>Moraxella catarrhalis</em>, may play a role in the pathogenesis of NLPHL, based on identification of B cell receptors expressed by LP cells that specifically recognize Moraxella antigens in a subset of cases [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell signaling and cytokine production</strong> – Like normal GCB cells, growth and survival of LP cells appear to depend on signals produced by the Ig receptor and interactions with dendritic cells and follicular T cells within B cell follicles [<a href="#rid15">15</a>]. By contrast, HRS cells of cHL lack Ig receptor signaling and instead depend on signals transmitted by other receptors (eg, CD30 and CD40 or, in Epstein-Barr virus [EBV]-associated cases, the EBV-encoded protein LMP1) to activate the transcription factor nuclear factor kappa-B (NF-kB) [<a href="#rid16">16,17</a>]. </p><p></p><p class="bulletIndent1">LP cells are not a rich source of proinflammatory cytokines and chemokines, and as a result, systemic B symptoms (eg, fever, sweats, weight loss) are not typically associated with NLPHL. This contrasts with the broad array of inflammatory cytokines and chemokines produced by HRS cells of cHL, which have both local and systemic effects. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma", section on 'Cytokines/chemokines'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymph node milieu </strong>– LP cells are typically found within expanded B cell follicles that are rich in follicular dendritic cells and CD4+, CD57+, PD1+ follicular helper T cells. Crosstalk between LP cells and the surrounding reactive cells differs from that of HRS cells despite their shared origins as transformed GCB cells. </p><p></p><p class="bulletIndent1">Progressive transformation of germinal centers (PTGC) has been described in patients who later develop NLPHL, but the nature of the association of PTGC with NLPHL is uncertain [<a href="#rid18">18</a>]. (See <a class="local">'Progressive transformation of germinal centers'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus </strong>– EBV is rarely detected in NLPHL, whereas EBV is detected in many cases of cHL, particularly the mixed cellularity and lymphocyte depleted subtypes [<a href="#rid3">3,19-21</a>]. Rare cases of EBV-associated NLPHL generally have atypical features that are reminiscent of lymphocyte-rich cHL [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/4698.html" rel="external">"Pathogenesis of Hodgkin lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The following symptoms and signs were present at diagnosis in the two largest series of patients with NLPHL [<a href="#rid23">23-25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphadenopathy</strong> – Lymphadenopathy (present in 100 percent of patients) tends to present as a chronic, asymptomatic lymphadenopathy involving peripheral lymph nodes (above or below the diaphragm) that are easily detected by physical examination [<a href="#rid23">23-25</a>]. In contrast, central lymph node involvement is less common, with a mediastinal mass present in only 2 to 7 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constitutional (B) symptoms</strong> – B symptoms (fever, drenching night sweats, weight loss) are uncommon at presentation (6 to 15 percent) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'B symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organomegaly</strong> – Organomegaly is uncommon, with spleen involvement in 8 percent and liver involvement in 2 to 3 percent [<a href="#rid6">6,26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow</strong> – Bone marrow involvement by NLPHL is rare; marrow involvement has been reported in 1 to 2 percent of cases [<a href="#rid6">6,26,27</a>]. </p><p></p><p class="bulletIndent1">In a study of 275 patients diagnosed with NLPHL, only seven patients with purely nodular NLPHL had bone marrow involvement [<a href="#rid27">27</a>]. Notably, patients with marrow involvement typically had prior clinical, laboratory, radiologic, or morphologic evidence of aggressive disease or hematologic abnormalities. At least some of these patients may have actually had T cell/histiocyte-rich B cell lymphoma (T/HRBCL; a variant of diffuse large B cell lymphoma), which commonly involves bone marrow and the spleen and may be difficult to distinguish from NLPHL. (See <a class="local">'T cell/HRBCL'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung involvement</strong> – Lung involvement, which can be manifest as a pulmonary lymphoid infiltrate, has been reported in 1 to 4 percent of patients at presentation [<a href="#rid6">6,26,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone</strong> – Skeletal involvement was reported in 1 to 3 percent of patients [<a href="#rid6">6,26</a>].</p><p></p><p>Approximately 75 percent of patients with NLPHL present with early stage disease (ie, stages I or II) (<a class="graphic graphic_table graphicRef66651" href="/z/d/graphic/66651.html" rel="external">table 1</a>) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H5"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Histologic and immunophenotypic characteristics are the bases for distinguishing NLPHL (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 2</a>) from classic Hodgkin lymphoma (cHL).</p><p class="headingAnchor" id="H9"><span class="h2">Morphology</span><span class="headingEndMark"> — </span>In NLPHL, the lymph node architecture is totally or partially replaced by a nodular or mixed nodular and diffuse infiltrate composed predominantly of small lymphocytes, macrophages, and epithelioid histiocytes admixed with variable numbers of intermingled lymphocyte predominant (LP) cells [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H10"><span class="h3">LP cells</span><span class="headingEndMark"> — </span>A key morphologic feature of NLPHL is the presence of LP cells (<a class="graphic graphic_picture graphicRef82911" href="/z/d/graphic/82911.html" rel="external">picture 1</a>) (also called "popcorn cells" because the nucleus resembles an exploded popcorn kernel), which are the malignant component of NLPHL. LP cells are large and usually have a single large vesicular, polylobulated nucleus and distinct but small and usually peripheral nucleoli, without perinucleolar halos [<a href="#rid29">29</a>]. The presence of LP cells is required for the diagnosis of NLPHL, but cells with similar morphology can be seen in other disorders. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h3">Background cells</span><span class="headingEndMark"> — </span>NLPHL is characterized by scattered LP cells in a background of small B lymphocytes, follicular dendritic cells, and CD4+, CD57+, PD1+ follicular helper T lymphocytes, which often form rosettes around the LP cells [<a href="#rid30">30</a>]. By contrast, the histology of cHL is typically characterized by scattered Hodgkin/Reed-Sternberg (HRS) cells in a polymorphous background of acute and chronic inflammatory cells. </p><p class="headingAnchor" id="H12"><span class="h3">Growth pattern</span><span class="headingEndMark"> — </span>Over 80 percent of cases of NLPHL have a distinctly nodular architecture. The nodular pattern is enhanced by stains for follicular dendritic cell markers (eg, CD21, CD23), which typically highlights expanded follicles that are rich in small resting B cells and LP cells (<a class="graphic graphic_picture graphicRef67339" href="/z/d/graphic/67339.html" rel="external">picture 3</a>). </p><p>Variant growth patterns of NLPHL have been described that are often associated with higher-stage disease, greater incidence of recurrence, and worse overall outcome [<a href="#rid31">31</a>]. In some of these variants, a predominantly diffuse architecture is seen, and such cases may be difficult to distinguish from other entities, such as the lymphocyte-rich variant of cHL and T cell/histiocyte-rich B cell lymphoma [<a href="#rid2">2</a>]. In other instances, typical NLPHL acquires a diffuse growth pattern as part of a transformation to diffuse large B cell lymphoma (DLBCL) or T cell/histiocyte-rich B cell lymphoma (T/HRBCL) [<a href="#rid32">32</a>]. In cases of transformation to DLBCL, the mutational profile of the transformed tumor resembles that of germinal center B (GCB) subtype of DLBCL [<a href="#rid33">33</a>]. (See <a class="local">'T cell/HRBCL'</a> below.)</p><p>It is uncertain if purely diffuse cases of NLPHL exist [<a href="#rid34">34</a>]. In the World Health Organization (WHO) classification, it is recommended that diffuse cases that lack admixed follicular dendritic cells be classified as T/HRBCL rather than NLPHL [<a href="#rid35">35</a>]. (See <a class="local">'Lymphocyte-rich classic HL'</a> below.) </p><p class="headingAnchor" id="H13"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>The characteristic immunophenotype of LP cells is an important aspect of distinguishing NLPHL from cHL. </p><p>LP cells express the B cell antigens (CD19, CD20, CD22, CD79a), CD45 (leukocyte common antigen), and the transcription factors BOB-1 and OCT-2; they do not express CD15 and they rarely express CD30 (<a class="graphic graphic_picture graphicRef78028" href="/z/d/graphic/78028.html" rel="external">picture 4</a>) [<a href="#rid3">3,36</a>]. By contrast, HRS cells of cHL are typically CD15+, CD30+, CD45-, CD20- and usually lose expression of BOB-1 and/or OCT-2 (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Nodular lymphocyte-predominant HL'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>NLPHL may be suspected in a patient with chronic, asymptomatic peripheral lymphadenopathy.</p><p>Diagnosis requires demonstration of the characteristic morphologic and immunophenotypic features on a lymph node biopsy. We strongly encourage an excisional lymph node biopsy for the diagnosis of NLPHL, when possible. Distinguishing NLPHL from other conditions in the differential diagnosis relies on morphologic differences that may be difficult to appreciate in core biopsies and fine needle aspiration (FNA). Because NLPHL is an uncommon disease, it is most reliably diagnosed by an experienced hematopathologist.</p><p>The following features are components of the diagnosis of NLPHL (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 2</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histology</strong> – The presence of neoplastic lymphocyte predominant (LP) cells within the background of a fully or partially nodular growth pattern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype</strong> – LP cells are typically CD20+, CD45+, CD15-, and CD30-. An expanded set of markers, including epithelial membrane antigen (EMA) and other B cell markers, such as CD79a and the transcription factors BOB-1 and OCT-2, can be helpful in ambiguous cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellular milieu</strong> – Background cells primarily consist of small B lymphocytes; CD3+, CD4+, CD57+, PD1+ follicular helper T cells; and CD21+, CD23+ follicular dendritic cells. Although flow cytometry is of limited utility in diagnosing NLPHL, background activated CD4+ T cells sometimes express low levels of CD8, which can be a clue to the presence of NLPHL.</p><p></p><p class="headingAnchor" id="H15"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of NLPHL includes both non-malignant and malignant causes of lymphadenopathy. It is particularly important to distinguish NLPHL from lymphomas with a distinctive prognosis and those that require different treatment (<a class="graphic graphic_table graphicRef57098" href="/z/d/graphic/57098.html" rel="external">table 3</a>). The importance of an excisional lymph node biopsy to distinguish NLPHL from other conditions in the differential diagnosis is discussed above. (See <a class="local">'Diagnosis'</a> above.)</p><p>Most patients with NLPHL present with peripheral lymphadenopathy. The numerous other causes of lymphadenopathy include infectious, autoimmune, benign, and malignant conditions. A general approach to the evaluation of lymphadenopathy in adults is presented separately. (See  <a class="medical medical_review" href="/z/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Progressive transformation of germinal centers</span><span class="headingEndMark"> — </span>Progressive transformation of germinal centers (PTGC) is an uncommon condition that is often associated with a chronic inflammatory or autoimmune disorder. It typically presents as unexplained, asymptomatic, persistent, or recurrent lymphadenopathy. Lymph node biopsy of PTGC is characterized by at least one enlarged follicle (ie, three to five times the size of a normal reactive follicle) showing a predominance of small mantle zone B cells that become admixed with, and eventually replace, the underlying germinal center [<a href="#rid37">37,38</a>]. While some patients with PTGC may later develop NLPHL or another lymphoma, PTGC is not considered to be a premalignant condition.</p><p>The absence of lymphocyte predominant (LP) cells distinguishes PTGC from NLPHL, but malignant LP cells may be missed on initial pathologic review. Biopsies interpreted as PTGC should be re-evaluated to make certain that a diagnosis of NLPHL is not missed.</p><p class="headingAnchor" id="H18"><span class="h2">T cell/HRBCL</span><span class="headingEndMark"> — </span>T cell/histiocyte-rich B cell lymphoma (T/HRBCL) is a variant of diffuse large B cell lymphoma (DLBCL) that can be challenging to distinguish from NLPHL because of similar morphology and an identical immunophenotype; some experts consider these tumors to be part of a biologic continuum [<a href="#rid34">34,39</a>]. In support of this idea, T/HRBCL is associated with mutations in <em>JUNB, DUSP2, SGK1</em>, and <em>SOCS1</em>, the same genes that appear to be commonly mutated in NLPHL [<a href="#rid40">40</a>]. </p><p>It is important to distinguish T/HRBCL from NLPHL because of their distinct natural histories and different treatment approaches. Because the growth pattern is difficult to ascertain in core needle biopsies, surgical lymph node biopsy may be needed. NLPHL usually presents as low-stage disease and follows an indolent course, whereas most cases of T/HRBCL present as high-stage disease and have poorer outcomes [<a href="#rid41">41</a>]. The key features that distinguish T/HRBCL from NLPHL are the growth pattern (<a class="graphic graphic_table graphicRef57098" href="/z/d/graphic/57098.html" rel="external">table 3</a>) and composition of the background cells [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth pattern</strong> – The growth pattern in T/HRBCL is diffuse, whereas the growth pattern in NLPHL is usually at least partially nodular [<a href="#rid3">3,21</a>]. Because the growth pattern is difficult to ascertain in core needle biopsies, lymph node biopsy may be necessary to arrive at a definitive diagnosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant cells</strong> – In both T/HRBCL and NLPHL, involved nodes contain scattered neoplastic CD20+ B cells within a reactive background. The neoplastic cells in T/HRBCL can resemble LP cells, but they may also appear like centroblasts, immunoblasts, or the Hodgkin/Reed-Sternberg (HRS) cells of classic Hodgkin lymphoma (cHL). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background cells</strong> – The background cells in T/HRBCL differ from those of NLPHL. In T/HRBCL, the background cells are predominantly CD8+ cytotoxic T cells and macrophages, while follicular dendritic cells are absent. By contrast, the typical background of NLPHL consists primarily of small B lymphocytes; CD3+, CD4+, CD57+, PD1+ follicular helper T cells; and follicular dendritic cells. </p><p></p><p>The World Health Organization (WHO) classification system acknowledges that NLPHL occasionally transforms to a tumor identical in appearance and immunophenotype to T/HRBCL and recommends that such cases be diagnosed as T/HRBCL-like transformations [<a href="#rid3">3</a>]. Such transformation is associated with the loss of background dendritic cells. </p><p class="headingAnchor" id="H19"><span class="h2">Lymphocyte-rich classic HL</span><span class="headingEndMark"> — </span>Lymphocyte-rich classic Hodgkin lymphoma (LRCHL) is a variant of cHL that can be difficult to distinguish from NLPHL [<a href="#rid42">42</a>]. Both conditions have similar clinical presentations, including predominantly early stage, nonbulky disease, and absence of B symptoms. Histologically, LRCHL contains characteristic HRS cells in a background of small lymphocytes with a predominantly nodular pattern although, occasionally, it can be diffuse. Typical LP cells are not seen.</p><p>In addition to the presence of characteristic HRS cells and the absence of LP cells, immunophenotypic differences help to distinguish LRCHL from NLPHL (<a class="graphic graphic_table graphicRef57098" href="/z/d/graphic/57098.html" rel="external">table 3</a>). LRCHL is also much more likely to be positive for Epstein-Barr virus (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Immunophenotype'</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Staging of NLPHL is based on clinical evaluation, laboratory studies, and positron emission tomography (PET)/computed tomography (CT) according to Lugano criteria (<a class="graphic graphic_table graphicRef66651" href="/z/d/graphic/66651.html" rel="external">table 1</a>). Bone marrow examination is not routinely performed unless there are unexplained cytopenias or other suspicion for marrow involvement. </p><p>Additional details of staging are provided separately. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The history should include documentation of constitutional (B) symptoms (fever, sweats, weight loss), and physical examination should evaluate all accessible lymph node stations, liver, and spleen.</p><p class="headingAnchor" id="H22"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>The following laboratory studies should be obtained:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood cell count with differential</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum chemistries – Chemistries should include serum electrolytes, glucose, renal and liver function tests, lactate dehydrogenase (LDH), and calcium </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viral studies – HIV and viral hepatitis tests</p><p></p><p class="headingAnchor" id="H1958828102"><span class="h2">PET/CT</span><span class="headingEndMark"> — </span>PET/CT should be performed to document regions of lymph node and organ involvement [<a href="#rid43">43,44</a>]. </p><p class="headingAnchor" id="H172999745"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/120313.html" rel="external">"Society guideline links: Management of Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype (approximately 5 percent) of Hodgkin lymphoma (HL). NLPHL differs importantly from the other subtypes of HL, which are referred to collectively as classic HL (cHL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – NLPHL accounts for approximately 5 percent of Hodgkin lymphoma. It has a bimodal age distribution (childhood and age 30 to 40 years), and it is more common in males than females. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The malignant cells of NLPHL (named LP cells) are derived from germinal center B (GCB) cells. LP cells are typically found within expanded B cell follicles that are rich in follicular dendritic cells and a distinctive population of CD3+, CD4+, CD57+ T cells. LP cells appear to depend on immunoglobulin receptor signaling for growth and survival. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – NLPHL generally presents as chronic, asymptomatic peripheral lymphadenopathy that is detectable by physical examination. Mediastinal, splenic, liver, and bone marrow involvement and constitutional (B) symptoms are uncommon. Most patients present with early-stage disease (ie, stage I or II). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – A key morphologic feature of NLPHL is the presence of LP cells (<a class="graphic graphic_picture graphicRef82911" href="/z/d/graphic/82911.html" rel="external">picture 1</a>) (also called popcorn cells, due to their microscopic appearance) with a characteristic immunophenotype, in the context of a fully or partially nodular growth pattern and with a background of predominantly small B lymphocytes, follicular helper T cells, and follicular dendritic cells. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – NLPHL may be suspected in a patient with chronic, asymptomatic peripheral lymphadenopathy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Diagnosis requires an excisional lymph node biopsy; core biopsies and fine needle aspiration are generally not sufficient to distinguish NLPHL from other disorders. </p><p></p><p class="bulletIndent1">Diagnosis includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Histology</strong> – LP cells within the background of a fully or partially nodular growth pattern.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunophenotype</strong> – LP cells are typically CD20+, CD45+, CD15-, and CD30-. </p><p></p><p class="bulletIndent2">Additional markers (eg, epithelial membrane antigen [EMA], CD79a, BOB-1, OCT-2) can be helpful in ambiguous cases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cellular milieu</strong> – Background cells that primarily consist of small B lymphocytes, CD3+, CD4+, CD57+, PD1+ follicular helper T cells; and CD21+, CD23+ follicular dendritic cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes nonmalignant and malignant causes of lymphadenopathy (<a class="graphic graphic_table graphicRef57098" href="/z/d/graphic/57098.html" rel="external">table 3</a>). The distinction between NLPHL and other conditions is best made by an experienced hematopathologist. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">NLPHL should be distinguished from:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progressive transformation of germinal centers </strong>(see <a class="local">'Progressive transformation of germinal centers'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T cell/histiocyte-rich B cell lymphoma</strong> (see <a class="local">'T cell/HRBCL'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphocyte-rich cHL</strong> (<a class="graphic graphic_table graphicRef57079" href="/z/d/graphic/57079.html" rel="external">table 2</a>) (see <a class="local">'Lymphocyte-rich classic HL'</a> above)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – Staging is based on clinical evaluation, laboratory studies, and positron emission tomography (PET)/CT, according to Lugano criteria (<a class="graphic graphic_table graphicRef66651" href="/z/d/graphic/66651.html" rel="external">table 1</a>). Bone marrow examination is not routinely performed unless there are unexplained cytopenias or other suspicion of marrow involvement. (See <a class="local">'Staging'</a> above.)</p><p></p><p class="headingAnchor" id="H3735029259"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate acknowledges the contributions of the late Peter M Mauch, MD, who was a previous author for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Falini B, Martino G, Lazzi S. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia 2023; 37:18.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.</a></li><li><a class="nounderline abstract_t">Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.</a></li><li><a class="nounderline abstract_t">Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776.</a></li><li><a class="nounderline abstract_t">Saarinen S, Pukkala E, Vahteristo P, et al. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2013; 31:938.</a></li><li><a class="nounderline abstract_t">Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 1997; 94:9337.</a></li><li><a class="nounderline abstract_t">Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997; 337:453.</a></li><li><a class="nounderline abstract_t">Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997; 337:459.</a></li><li><a class="nounderline abstract_t">Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 2003; 101:706.</a></li><li><a class="nounderline abstract_t">Mottok A, Renné C, Willenbrock K, et al. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 2007; 110:3387.</a></li><li><a class="nounderline abstract_t">Hartmann S, Schuhmacher B, Rausch T, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia 2016; 30:844.</a></li><li><a class="nounderline abstract_t">Thurner L, Hartmann S, Fadle N, et al. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. Nat Commun 2020; 11:2465.</a></li><li><a class="nounderline abstract_t">Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009; 4:151.</a></li><li><a class="nounderline abstract_t">Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008; 205:2251.</a></li><li><a class="nounderline abstract_t">Pratt ZL, Zhang J, Sugden B. The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells. J Virol 2012; 86:4380.</a></li><li><a class="nounderline abstract_t">Miettinen M, Franssila KO, Saxén E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983; 51:2293.</a></li><li><a class="nounderline abstract_t">Weiss LM, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991; 139:1259.</a></li><li><a class="nounderline abstract_t">Uccini S, Monardo F, Stoppacciaro A, et al. High frequency of Epstein-Barr virus genome detection in Hodgkin's disease of HIV-positive patients. Int J Cancer 1990; 46:581.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Huppmann AR, Nicolae A, Slack GW, et al. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol 2014; 38:316.</a></li><li><a class="nounderline abstract_t">Regula DP Jr, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988; 318:214.</a></li><li><a class="nounderline abstract_t">Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 1993; 71:2062.</a></li><li><a class="nounderline abstract_t">Borg-Grech A, Radford JA, Crowther D, et al. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1989; 7:1303.</a></li><li><a class="nounderline abstract_t">Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005; 23:5739.</a></li><li><a class="nounderline abstract_t">Khoury JD, Jones D, Yared MA, et al. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 2004; 28:489.</a></li><li><a class="nounderline abstract_t">Li G, Hansmann ML. Lymphocyte predominant Hodgkin's disease of nodular subtype combined with pulmonary lymphoid infiltration and hypogammaglobulinaemia. Virchows Arch A Pathol Anat Histopathol 1989; 415:481.</a></li><li><a class="nounderline abstract_t">Falini B, Bigerna B, Pasqualucci L, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996; 87:465.</a></li><li><a class="nounderline abstract_t">Nogová L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006; :266.</a></li><li><a class="nounderline abstract_t">Hartmann S, Eichenauer DA, Plütschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013; 122:4246.</a></li><li><a class="nounderline abstract_t">Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28:793.</a></li><li><a class="nounderline abstract_t">Song JY, Egan C, Bouska AC, et al. Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. Leukemia 2020; 34:2238.</a></li><li><a class="nounderline abstract_t">Boudová L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003; 102:3753.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Hartmann S, Eichenauer DA, Plütschow A, et al. Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG). Br J Haematol 2014; 167:238.</a></li><li><a class="nounderline abstract_t">Hicks J, Flaitz C. Progressive transformation of germinal centers: review of histopathologic and clinical features. Int J Pediatr Otorhinolaryngol 2002; 65:195.</a></li><li><a class="nounderline abstract_t">Verma A, Stock W, Norohna S, et al. Progressive transformation of germinal centers. Report of 2 cases and review of the literature. Acta Haematol 2002; 108:33.</a></li><li><a class="nounderline abstract_t">Rüdiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002; 13 Suppl 1:44.</a></li><li><a class="nounderline abstract_t">Schuhmacher B, Bein J, Rausch T, et al. JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. Haematologica 2019; 104:330.</a></li><li><a class="nounderline abstract_t">Maes B, Anastasopoulou A, Kluin-Nelemans JC, et al. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features. Ann Oncol 2001; 12:853.</a></li><li><a class="nounderline abstract_t">de Jong D, Bosq J, MacLennan KA, et al. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Ann Oncol 2006; 17:141.</a></li><li><a class="nounderline abstract_t">Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3048.</a></li><li><a class="nounderline abstract_t">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</a></li></ol></div><div id="topicVersionRevision">Topic 4730 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36460764" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36460764" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150940" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664057" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071266" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23284040" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256483" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250847" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250848" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clonality in nodular lymphocyte-predominant Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393409" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652621" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26658840" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32424289" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400691" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794340" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318153" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6850508" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1661073" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2170278" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : High frequency of Epstein-Barr virus genome detection in Hodgkin's disease of HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24525501" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336412" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nodular and diffuse types of lymphocyte predominance Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8443755" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2769329" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009944" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15087668" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2508307" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lymphocyte predominant Hodgkin's disease of nodular subtype combined with pulmonary lymphoid infiltration and hypogammaglobulinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555467" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17124071" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100447" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048177" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054999" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881319" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24965443" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12242134" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Progressive transformation of germinal centers: review of histopathologic and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145465" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Progressive transformation of germinal centers. Report of 2 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12078902" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30213827" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11484964" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284059" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113771" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113753" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
